BRCA1 and metastatic prostate carcinoma: A significant survival benefit has been demonstrated in men with castrate-resistant metastatic prostate cancer and germline variants in BRCA1/2 when treated with the poly (ADP-ribose) polymerase inhibitor olaparib36; this same survival benefit has not been observed among men with variants in ATM.